코스닥 이야기
Quickly browse recent reports in the selected category.
-
2026-03-25 US 10-Year Treasury Yield and Tech Stock Report
KOSDAQ Story: The US 10-year yield tantrum and the tech stock dilemma. Daily Stock analyzes the latest macroeconomic variables and key KOSDAQ trends, checking growth stock valuations amid rising interest rates and geopolitical risks.
-
Analysis of the Extreme Volatility in Secondary Battery Material Stocks: Kosdaq's Dilemma Between the EV Chasm and the ESS Boom
Hello, I'm an expert writer at Daily Stock. Today, we delve into the extreme volatility of secondary battery material stocks heating up the Kosdaq, exploring the structural changes driven by the EV chasm and explosive ESS demand.
-
KOSDAQ Challenges 1,100 Mark: Checking Earnings Momentum and Valuation of AI Software Growth Stocks
As an expert writer for DailyStock, I will examine the earnings momentum of KOSDAQ AI software companies. As of March 2026, the sector has entered a phase of proving actual earnings beyond mere technical expectations.
-
![[KOSDAQ Story] Responding to the KOSDAQ 150 Volatility Expansion Phase: Analysis of Active ETF Supply/Demand and Foreign Program Trading](https://daily-stock.kr/stdaily/uploads/202603/gen_69be507c42df05.62814958.png)
[KOSDAQ Story] Responding to the KOSDAQ 150 Volatility Expansion Phase: Analysis of Active ETF Supply/Demand and Foreign Program Trading
Hello, as a professional writer for Daily Stock, I welcome you all who are contemplating successful investment strategies today. Image generation: "A 16:9 thumbnail image for a financial blog, showing a dramatic stock chart ...
-
![[KOSDAQ Retail Top Net Purchases Review] The Majesty of 1st Place Beating Ecopro, Analysis of Samchundang Pharm's Oral Insulin Momentum](https://daily-stock.kr/stdaily/uploads/202603/gen_69bcfefd8fdfb1.30890448.png)
[KOSDAQ Retail Top Net Purchases Review] The Majesty of 1st Place Beating Ecopro, Analysis of Samchundang Pharm's Oral Insulin Momentum
Hello, this is Daily Stock. We review the strong net buying trend of retail investors defending the KOSDAQ 1160 line amid NASDAQ's extreme fear, focusing on Samchundang Pharm using the latest data as of March 20, 2026.
-
KOSDAQ Surpasses 1140: Examining the 'Reversal Bets' in Retail Investors' Portfolios
Hello, I'm an expert writer for Daily Stock. Today, we examine the trends and backgrounds of key stocks heavily net-bought by retail investors as the KOSDAQ breaks the 1140 mark.